215 related articles for article (PubMed ID: 33741208)
21. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
Sonawane K; Castellano T; Washington C; Ting J; Surinach A; Kirshner C; Chhatwal J; Ayer T; Moore K
Gynecol Oncol Rep; 2022 Dec; 44(Suppl 1):101101. PubMed ID: 36506039
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
Sonawane K; Castellano T; Washington C; Ting J; Surinach A; Kirshner C; Chhatwal J; Ayer T; Moore K
Gynecol Oncol Rep; 2022 Dec; 44():101121. PubMed ID: 36589508
[TBL] [Abstract][Full Text] [Related]
23. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
[TBL] [Abstract][Full Text] [Related]
24. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.
Ma E; Bonthapally V; Chawla A; Lefebvre P; Swords R; Lafeuille MH; Fortier J; Emond B; Duh MS; Dezube BJ
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):625-636.e3. PubMed ID: 27686689
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Tinker AV; Fiorino L; O'Dwyer H; Kumar A
Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
[TBL] [Abstract][Full Text] [Related]
26. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study.
Flannery K; Boyd M; Black-Shinn J; Robert N; Kamat AM
Future Oncol; 2019 Apr; 15(12):1323-1334. PubMed ID: 30942088
[No Abstract] [Full Text] [Related]
27. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
28. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
Vergote I; Van Nieuwenhuysen E; O'Cearbhaill RE; Westermann A; Lorusso D; Ghamande S; Collins DC; Banerjee S; Mathews CA; Gennigens C; Cibula D; Tewari KS; Madsen K; Köse F; Jackson AL; Boere IA; Scambia G; Randall LM; Sadozye A; Baurain JF; Gort E; Zikán M; Denys HG; Ottevanger N; Forget F; Mondrup Andreassen C; Eaton L; Chisamore MJ; Viana Nicacio L; Soumaoro I; Monk BJ
J Clin Oncol; 2023 Dec; 41(36):5536-5549. PubMed ID: 37651655
[TBL] [Abstract][Full Text] [Related]
29. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.
Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
Future Oncol; 2019 Mar; 15(9):1021-1034. PubMed ID: 30757910
[TBL] [Abstract][Full Text] [Related]
32. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
33. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.
Fisher MD; Pulgar S; Kulke MH; Mirakhur B; Miller PJ; Walker MS; Schwartzberg LS
J Gastrointest Cancer; 2019 Dec; 50(4):816-823. PubMed ID: 30121904
[TBL] [Abstract][Full Text] [Related]
34. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
35. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
Wells JC; Dudani S; Gan CL; Stukalin I; Azad AA; Liow E; Donskov F; Yuasa T; Pal SK; De Velasco G; Hansen AR; Beuselinck B; Kollmannsberger CK; Powles T; McGregor BA; Duh MS; Huynh L; Heng DYC
Clin Genitourin Cancer; 2021 Aug; 19(4):354-361. PubMed ID: 33863648
[TBL] [Abstract][Full Text] [Related]
36. Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study.
Waddell T; Fife K; Griffiths R; Sharma A; Dhokia P; Groves L; Hurst M; Tsang C; Sugrue D; McKenna S; Houghton J; Carroll R
BMC Cancer; 2022 Jun; 22(1):617. PubMed ID: 35668384
[TBL] [Abstract][Full Text] [Related]
37. Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
Monk BJ; Smith G; Lima J; Long GH; Alam N; Nakamura H; Meulendijks D; Ghiorghiu D; Banerjee S
Gynecol Oncol; 2022 Feb; 164(2):325-332. PubMed ID: 34952707
[TBL] [Abstract][Full Text] [Related]
38. Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States.
Liu J; Emond B; Maiese EM; Lafeuille MH; Lefebvre P; Ghelerter I; Wu C; Hurteau JA; Thaker PH
Curr Med Res Opin; 2022 Nov; 38(11):1935-1945. PubMed ID: 35975577
[TBL] [Abstract][Full Text] [Related]
39. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer.
McLean J; Rho YS; Kuruba G; Mamo A; Gilabert M; Kavan T; Panasci L; Melnychuk D; Batist G; Kavan P
Clin Colorectal Cancer; 2016 Jun; 15(2):135-40. PubMed ID: 26553578
[TBL] [Abstract][Full Text] [Related]
40. Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: A retrospective, community oncology-based cohort study (A STROBE-compliant article).
Cowey CL; Liu FX; Boyd M; Aguilar KM; Krepler C
Medicine (Baltimore); 2019 Jul; 98(28):e16328. PubMed ID: 31305421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]